31 August 2021: Clinical Research
Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience
Wojciech Straś 1ACDE , Joanna Gotlib 2ACEF , Piotr Małkowski 3ACDEFG* , Dariusz Wasiak 3CDE , Andrzej Śliwczyński 3BCDE , Mariusz Panczyk 2ACDE , Olga Tronina 4EF , Melania Brzozowska 5BCDDOI: 10.12659/MSM.931856
Med Sci Monit 2021; 27:e931856
Table 1 Therapy duration summary.
| Comments | ||
|---|---|---|
| Minimum | 14 days | |
| Maximum | 2800 days | |
| Median (50% patients) | 111 days | |
| Mean | 225.8 days | 95% CL: 207.71–243.97 |
| Observation period | 2946 days |